Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon Research Institute of Colorado ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

University of Pennsylvania spinout Verismo Therapeutics is being acquired by South Korea-based HLB Group, which already owns an almost 50 percent stake in the firm, writes John George for the ...

Subjects will be divided into two cohorts, with each cohort consisting of three to six individuals. Credit: Volha_R/Shutterstock. Verismo Therapeutics has commenced the first patient dosing in its ...

University of Pennsylvania spinout Verismo Therapeutics is being acquired by South Korea-based HLB Group, which already owns an almost 50 percent stake in the firm, writes John George for the ...

If you’re looking to make your own drinks at home, one of the best espresso machines can help you turn your kitchen into your own personal coffee shop. Our favorite pick overall in 2025 ...

Verismo Therapeutics is developing T-cell therapeutics for the treatment of solid ... stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a ...

10, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has dosed the first patient in its CELESTIAL-301 ...

As with so many other products at CNET, we test rowing machines as thoroughly as possible, through rigorous examination and comparison. Each rowing machine in our list has been through at least ...